Q-omics provides the consensus-scored SRPK2P profile across patient tissues and cancer cell-line models. SRPK2P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, SRPK2P is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, SRPK2P RNA expression shows 14,306 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ESCA, LIHC, and THYM as cancer lineages where SRPK2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRPK2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRPK2P survival associations across molecular data types. SRPK2P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRPK2P RNA expression–survival associations across cancer types. High SRPK2P expression shows unfavorable associations in KICH, CHOL, HNSC, ACC and LUAD, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for SRPK2P RNA expression.
This table summarizes SRPK2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SRPK2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRPK2P shows higher tumor expression in LIHC, KIRP, LUAD, STAD, BRCA and LUSC. The LIHC box plot shows higher SRPK2P RNA expression in tumor versus normal tissue (log2 FC = +0.125, t-test p < 0.001).
This table shows molecular features associated with SRPK2P in patient tissues and cancer cell lines. In patient samples, SRPK2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
